

Baxter International Inc.
Key Product Line Sales
Period Ending September 30, 2004
(unaudited)

(\$ in millions)	Q3 2004	Q3 2003	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2004	YTD 2003	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$341	\$291	17%	13%	\$953	\$788	21%	15%
Plasma Proteins ¹	254	251	1%	(1%)	759	710	7%	3%
Antibody Therapy	82	77	6%	4%	252	215	17%	13%
Transfusion Therapies	124	133	(7%)	(9%)	400	403	(1%)	(5%)
Other ²	48	68	(29%)	(38%)	188	217	(14%)	(24%)
Total BioScience	\$849	\$820	4%	0%	\$2,552	\$2,333	9%	4%
Medication Delivery								
IV Therapies ³	\$275	\$275	0%	(3%)	\$845	\$794	6%	1%
Drug Delivery	186	175	6%	5%	548	504	9%	6%
Electronic Infusion Systems	227	196	16%	15%	610	550	11%	9%
Anesthesia	196	197	0%	(1%)	593	579	2%	2%
Other ⁴	102	102	0%	(5%)	322	303	6%	0%
Total Medication Delivery ⁵	\$986	\$945	4%	2%	\$2,918	\$2,730	7%	4%
Renal								
PD Therapy	\$361	\$339	7%	4%	\$1,063	\$977	9%	4%
HD Therapy	123	107	15%	8%	365	321	14%	7%
Other	1	5	(80%)	(100%)	10	12	(17%)	(42%)
Total Renal	\$485	\$451	8%	4%	\$1,438	\$1,310	10%	4%
TOTAL BAXTER	\$2,320	\$2,216	5%	2%	\$6,908	\$6,373	8%	4%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FioSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes oncology and other hospital-distributed products.

⁵ Sales of pain management products, which were previously included in Anesthesia, are now reported in Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.

Note: In August 2004, the company restated its previously issued financial statements for 2001 through 2003 and the first quarter of 2004. This information reflects the restatements. Refer to the company's Form 10-K/A for the year ended December 31, 2003 and Forms 10-Q/A for the quarters ended March 31, 2004 and September 30, 2003 for further information.